

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7685 - PERRIGO / GSK DIVESTMENT BUSINESSES

SECTION 1.2

Description of the concentration

- (1) On 22 July 2015, the Commission received a notification of a proposed concentration consisting in the acquisition of sole control of the assets constituting certain consumer healthcare businesses (the “**Divestment Businesses**”) of GlaxoSmithKline Consumer Healthcare Holdings Limited, which has its registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS (“**GSK**”), by Perrigo Company plc, a public limited company incorporated under the laws of Ireland, which has its registered office at Treasury Building, Lower Grand Canal St., Dublin 2, Ireland (“**Perrigo**”), with a view to implementing GSK’s commitments in relation to certain consumer healthcare businesses as described in the European Commission’s decision of 28 January 2015 in case M.7276 - *GlaxoSmithKline / Novartis Vaccines Business (excl. influenza) / Novartis Consumer Health Business* and its associated commitments. The proposed transaction constitutes a concentration by way of acquisition of sole control within the meaning of Article 3(1)(b) of the Merger Regulation.
- (2) Perrigo is an international pharmaceuticals company with activities in the development, manufacture, and marketing of consumer healthcare and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients (APIs). Perrigo is active worldwide.
- (3) The Divestment Businesses comprise the following businesses: (i) GSK’s *NiQuitin* nicotine reduction therapy business; (ii) GSK’s *Coldrex* cold & flu business; (iii) GSK’s *Nasin* and *Nezeril* cold & flu business; (iv) GSK’s *Panodil* pain management business; and (v) Novartis’ topical cold sores management business (including the *Fenivir*, *Pencivir*, *Vectavir*, and *Vectatone* brands).